Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Area of Science:

• Hepatology and Viral Gastroenterology
• Clinical Pharmacology and Therapeutics
• Infectious Diseases Research

Background:

• Hepatitis C virus (HCV) infection presents distinct treatment challenges based on genotype.
• Previous studies indicated varying response rates for sofosbuvir-ribavirin combination therapy in HCV genotypes 2 and 3.
• Understanding optimal treatment durations is crucial for effective HCV management.

Purpose of the Study:

• To evaluate the efficacy of sofosbuvir-ribavirin in patients with HCV genotypes 2 and 3.
• To determine the sustained virologic response rates following different treatment durations.
• To assess treatment outcomes in patients with prior interferon-based therapy or cirrhosis.

Main Methods:

• A randomized study assigned 91 patients with HCV genotype 2 and 328 with HCV genotype 3 to sofosbuvir-ribavirin or placebo.
• Initial 12-week treatment was extended to 24 weeks for genotype 3 patients based on emerging data.
• The primary endpoint was sustained virologic response at 12 weeks post-therapy.

Main Results:

• High sustained virologic response rates were observed: 93% for genotype 2 (12 weeks) and 85% for genotype 3 (24 weeks).
• For genotype 3, response rates were 91% without cirrhosis and 68% with cirrhosis.
• Common adverse events included headache, fatigue, and pruritus.

Conclusions:

• Sofosbuvir-ribavirin is effective for treating HCV genotypes 2 and 3.
• A 12-week regimen is effective for genotype 2, while a 24-week regimen is recommended for genotype 3.
• The findings support the use of this combination therapy for specific HCV genotypes.